The Committee for Advanced Therapies' of the European Medicines Agency Reflection Paper on Management of Clinical Risks Deriving from Insertional Mutagenesis-Reference-Cited by-同舟云学术

The Committee for Advanced Therapies' of the European Medicines Agency Reflection Paper on Management of Clinical Risks Deriving from Insertional Mutagenesis

Published:2013-06 Issue:2 Volume:24 Page:47-54
ISSN:2324-8637
Container-title:Human Gene Therapy Clinical Development
language:en
Short-container-title:Human Gene Therapy Clinical Development

Author:

Aiuti Alessandro¹²³,Cossu Giulio⁴⁵,de Felipe Pablo¹⁶,Galli Maria Cristina¹⁷,Narayanan Gopalan⁴⁸,Renner Matthias¹⁹,Stahlbom Axel¹¹⁰,Schneider Christian K.⁴¹¹¹²,Voltz-Girolt Caroline¹

Affiliation:

1. Gene Therapy Working Party of the Committee for Advanced Therapies, European Medicines Agency, 7, Westferry Circus E14 4HB, London, United Kingdom.

2. San Raffaele-Telethon Institute for Gene Therapy, Via Olgettina 58, 20132 Milan, Italy.

3. University Department of Pediatrics, Bambino Gesù Children's Hospital and Tor Vergata University, Rome, Italy.

4. Committee for Advanced Therapies, European Medicines Agency, 7, Westferry Circus E14 4HB, London, United Kingdom.

5. Department of Cell and Development Biology, University College London, Gower Street, London, WC1E 6BT United Kingdom.

6. Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.

7. Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy.

8. Medicines and Healthcare Products Regulatory Agency, 151 Buckingham Palace Road, Victoria, London, SW1W 9SZ United Kingdom.

9. Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, D-63225 Langen, Germany.

10. Läkemedelsverket (Medical Products Agency), Dag Hammarskjölds väg 42, 75103 Uppsala, Sweden.

11. Danish Health and Medicines Authority, Axel Heides Gade 1, 2300 Copenhagen, Denmark.

12. Twincore Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Straße 730625 Hannover, Germany.

Publisher

Mary Ann Liebert Inc

Subject

Genetics (clinical)

Link

http://www.liebertpub.com/doi/pdf/10.1089/humc.2013.119

Reference41 articles.

1. Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency

2. Gene therapy for primary immunodeficiencies: Part 2

3. Ocular gene delivery using lentiviral vectors

4. Concise Review: Managing Genotoxicity in the Therapeutic Modification of Stem Cells

5. Integration profile of retroviral vector in gene therapy treated patients is cell‐specific according to gene expression and chromatin conformation of target cell

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. hInGeTox: A human-based in vitro platform to evaluate lentivirus contribution to genotoxicity;2024-01-11

2. Pharmacovigilance of gene therapy medicinal products;Rare Disease and Orphan Drugs Journal;2023-11-23

3. T Cells Directed against the Metastatic Driver Chondromodulin-1 in Ewing Sarcoma: Comparative Engineering with CRISPR/Cas9 vs. Retroviral Gene Transfer for Adoptive Transfer;Cancers;2022-11-08

4. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy;Cell Reports Medicine;2021-08

5. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy;2020-12-14